Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AXSM | US
-6.65
-7.13%
Healthcare
Biotechnology
30/06/2024
04/10/2024
86.59
91.55
91.83
86.40
Axsome Therapeutics Inc. a biopharmaceutical company engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion) a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol) a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05 which is in Phase III clinical trial to treat Alzheimer's disease agitation as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07 an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12 an investigational medicine which is in Phase III trial to treat narcolepsy; AXS-14 a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol a dual-acting dopamine and norepinephrine reuptake inhibitor which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York New York.
View LessStrong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
47.0%1 month
43.6%3 months
34.3%6 months
34.1%-
-
41.83
1.86
0.35
-14.81
14.34
-
-261.38M
4.16B
4.16B
-
-87.06
-
86.70
-161.69
18.63
19.18
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
10.07
Range1M
10.60
Range3M
24.79
Rel. volume
1.75
Price X volume
71.77M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Denali Therapeutics Inc | DNLI | Biotechnology | 28.63 | 4.10B | -1.38% | n/a | 3.51% |
CRISPR Therapeutics AG | CRSP | Biotechnology | 45.37 | 3.86B | -0.74% | n/a | 11.68% |
Merus N.V | MRUS | Biotechnology | 51.78 | 3.53B | 2.41% | n/a | 1.48% |
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -14.81 | 0.76 | Cheaper |
Ent. to Revenue | 14.34 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 41.83 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 34.32 | 74.67 | Lower Risk |
Debt to Equity | 1.86 | -1.82 | Expensive |
Debt to Assets | 0.35 | 0.26 | Expensive |
Market Cap | 4.16B | 3.73B | Par |